Compass Pathways CEO says company will proceed cautiously as it readies psychedelic therapy for FDA review

Compass Pathways chief executive Kabir Nath told reporters at the STAT Summit that the company will "go slow before we go fast," emphasizing that early negative experiences could hurt the emerging psychedelics sector.

The firm is completing a rolling submission to the U.S. Food and Drug Administration this quarter for COMP360, a synthetic psilocybin product intended for patients with treatment-resistant depression, with a target launch early next year.

Nath said any approval would likely come with an FDA risk evaluation and mitigation strategy, and he believes the therapy could be a significant development for patients, providers, and the company itself.